Skip to Content

Eli Lilly and Co LLY

Morningstar Rating
$777.96 −0.22 (0.03%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

LLY is trading at a 55% premium.
Price
$773.14
Fair Value
$685.00
Uncertainty
High
1-Star Price
$373.00
5-Star Price
$975.00
Economic Moat
Yktd
Capital Allocation
Kmbqbtkjc

Bulls Say, Bears Say

Bulls

Lilly is developing a new Alzheimer’s drug (donanemab) that could become a major blockbuster, especially because the FDA appears to have a lower threshold for approval for this disease.

Bears

The risks to success for Alzheimer’s drug donanemab remain high both in clinical development and insurance coverage.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LLY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$778.18
Day Range
$776.44793.67
52-Week Range
$334.58800.78
Bid/Ask
$775.50 / $777.00
Market Cap
$739.66 Bil
Volume/Avg
3.2 Mil / 3.2 Mil

Key Statistics

Price/Earnings (Normalized)
92.72
Price/Sales
20.59
Dividend Yield (Trailing)
0.60%
Dividend Yield (Forward)
0.67%
Total Yield
0.70%

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
43,000

Competitors

Valuation

Metric
LLY
NVO
MRK
Price/Earnings (Normalized)
92.7247.5387.96
Price/Book Value
68.5736.188.89
Price/Sales
20.5917.125.59
Price/Cash Flow
96.3332.8322.09
Price/Earnings
LLY
NVO
MRK

Financial Strength

Metric
LLY
NVO
MRK
Quick Ratio
0.520.620.68
Current Ratio
0.940.821.25
Interest Coverage
14.13192.152.33
Quick Ratio
LLY
NVO
MRK

Profitability

Metric
LLY
NVO
MRK
Return on Assets (Normalized)
10.22%30.82%3.59%
Return on Equity (Normalized)
52.03%94.27%9.12%
Return on Invested Capital (Normalized)
19.27%72.84%5.88%
Return on Assets
LLY
NVO
MRK
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
JNJ
Johnson & JohnsonWmcdsbmQgp$381.2 Bil
MRK
Merck & Co IncLrvgskvzsQhr$334.2 Bil
ABBV
AbbVie IncYbzyxxlrYznb$322.4 Bil
AZN
AstraZeneca PLC ADRGfyyzlldWnbyl$208.8 Bil
RHHBY
Roche Holding AG ADRYyvcfryzthQhjnt$203.8 Bil
NVS
Novartis AG ADRRqlhmsdyLgzx$197.2 Bil
PFE
Pfizer IncWbpnvgycMcdk$157.1 Bil
AMGN
Amgen IncRvhbzzwcYqkw$152.4 Bil
SNY
Sanofi SA ADRGvtblxqzNsz$122.8 Bil

Sponsor Center